Ibogaine Clinical Trials 2025 — Texas UTHealth & Federal Research

Texas UTHealth Trials

The Texas Legislature's $50M appropriation funds clinical trials at UTHealth Houston — one of the nation's leading academic medical centers. These trials will produce the highest-quality evidence on ibogaine's safety and efficacy.

Stanford Veterans Study

The landmark 2023 Stanford study (Nayak et al.) found that ibogaine treatment produced dramatic reductions in PTSD, depression, and disability in US Special Operations veterans — the most rigorous ibogaine study to date.

VA/DoD Federal Research

The Trump executive order directing VA and DoD to study ibogaine for veterans has opened the door to federal clinical trials — potentially the largest and most rigorous ibogaine research ever conducted.

The Path to FDA Approval

Successful Phase 2 and Phase 3 clinical trials are required for FDA approval. The current wave of trials could produce Phase 2 data within 2–3 years, potentially supporting a Breakthrough Therapy designation that accelerates the approval timeline.

The Stanford Veterans Study: A Landmark

The 2023 Stanford study published in Nature Medicine (Nayak et al.) is the most rigorous ibogaine study to date. It enrolled 30 US Special Operations veterans who received ibogaine treatment in Mexico and found dramatic improvements in PTSD severity (88% reduction), depression (87% reduction), and disability (78% reduction) at one-month follow-up. No serious adverse events were reported.

The study's limitations — small sample size, no control group, open-label design — are acknowledged by the researchers. But the magnitude of the effects and the consistency of the results have generated enormous interest in the research community and among policymakers. It is widely credited with helping catalyze both the Texas $50M investment and the federal executive order.

What the Trials Will Study

The Texas UTHealth trials are expected to focus on ibogaine for opioid use disorder and PTSD — the two indications with the strongest existing evidence. The trials will likely include comprehensive cardiac monitoring, standardized dosing protocols, and structured integration support to maximize safety and efficacy.

The federal VA/DoD research will focus specifically on veterans with PTSD, TBI, and addiction. This population has been the most compelling case for ibogaine — and the political support from veterans advocacy groups has been crucial in advancing the research agenda.

When will the Texas UTHealth ibogaine trials begin?

The Texas Legislature appropriated $50M for ibogaine research in 2023. The trials are in the planning and regulatory approval phase. Actual patient enrollment is expected to begin in 2025–2026, with initial results available within 2–3 years of enrollment.

What conditions are the trials studying?

The primary focus is opioid use disorder and PTSD. Some trials may also study ibogaine for treatment-resistant depression, TBI, and alcohol use disorder. The exact protocols depend on the research institutions and regulatory approvals.

Will the trial results make ibogaine legal in Texas?

Clinical trial results alone do not change legal status. FDA approval requires successful Phase 2 and Phase 3 trials, followed by a formal approval process. State-level legalization in Texas would require separate legislative action. The trials are a necessary but not sufficient step toward legalization.

How can practitioners stay informed about the trial results?

Follow UTHealth Houston's research publications, the Multidisciplinary Association for Psychedelic Studies (MAPS), and the Ibogaine Alliance for updates on trial progress and results. TII will also publish updates on significant research developments.